Flu has overtaken covid in infections and hospitalizations during the winter respiratory virus season, and their virulence is ...

"As these viruses continue to evolve, public health officials watch carefully to see whether new strains will be more easily ...

A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in ...

The first known meta-analysis of how SARS-CoV-2 variant type and time since infection influence long-COVID symptoms ties Omicron to brain fog and paresthesia (numbness and tingling), while earlier ...

A new COVID-19 variant sweeping through China has yet to make a sizable footprint in the U.S., the Centers for Disease Control and Prevention (CDC) says. In January, a new COVID-19 variant known as NB ...

Some states are being hit harder than others this summer as a new COVID-19 strain (XGF) continues to spread. Some regions of the U.S. are still experiencing higher rates of positive COVID tests than ...

A commission said the country is still grappling with the long-term consequences of both the pandemic and the policy response ...

RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...

Discover the molecular mechanisms behind severe blood clots linked to specific COVID-19 vaccines, revealing crucial insights for future vaccine safety.

As COVID vaccines saved millions of lives, a small number of people began developing dangerous blood clots in unusual parts ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.